SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · Alpha Tau Medical reported H1 2026 financial results showing a net loss…

Alpha Tau Medical Ltd. · 6-K filed Aug 10, 2026 at 16:02 ET

At the news

BULLISHIMPACT 7/10

6-K filed Aug 10, 2026 at 16:02 ET

Alpha Tau Medical reported H1 2026 financial results showing a net loss of $68.8M ($0.76/share), widened from $18.8M ($0.25/share) in H1 2025, driven by a $42.2M non-cash remeasurement of warrant liabilities as the stock price rose above the $11.50 strike. Operating loss increased 42.9% to $27.1M on higher R&D spend ($20.9M vs $14.2M). The company ended Q2 with $104.8M in cash/short-term deposits, up from $76.9M at year-end 2025, boosted by a $20M equity investment from Tolmar at a 25% premium and $15M upfront payment under the Tolmar collaboration for U.S. prostate cancer commercialization. Key clinical catalysts include completed enrollment in the pivotal ReSTART trial (top-line data late 2026/early 2027), promising REGAIN glioblastoma interim data, and a 100% objective response rate in a head & neck combo study with pembrolizumab. The Tolmar deal provides up to $161.5M in milestones plus 60% of net sales on supply, validating the platform but also capping U.S. prostate cancer upside for Alpha Tau.

  • Net loss widened to $68.8M in H1 2026 from $18.8M in H1 2025, largely due to $42.2M non-cash warrant remeasurement.
  • Cash, cash equivalents, short-term deposits and restricted deposits totaled $104.8M as of June 30, 2026, up from $76.9M at Dec 31, 2025.
  • Tolmar collaboration: $20M equity investment at $11.99/share (25% premium to 30-day VWAP) + $15M for manufacturing capacity + up to $161.5M in milestones + 60% of net sales on supply.
  • Completed enrollment in U.S. pivotal ReSTART trial (88 patients) for recurrent cSCC; top-line data expected late 2026 or early 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access